LENALIDOMIDE-TEVA lenalidomide (as hydrochloride monohydrate) 7.5 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

lenalidomide-teva lenalidomide (as hydrochloride monohydrate) 7.5 mg capsule blister pack

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 9.075 mg - capsule - excipient ingredients: gelatin; croscarmellose sodium; purified talc; titanium dioxide; colloidal anhydrous silica; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

LENALIDOMIDE-TEVA lenalidomide (as hydrochloride monohydrate) 20 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

lenalidomide-teva lenalidomide (as hydrochloride monohydrate) 20 mg capsule blister pack

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 24.2 mg - capsule - excipient ingredients: croscarmellose sodium; indigo blue; colloidal anhydrous silica; microcrystalline cellulose; gelatin; titanium dioxide; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

LENALIDOMIDE-TEVA lenalidomide (as hydrochloride monohydrate) 2.5 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

lenalidomide-teva lenalidomide (as hydrochloride monohydrate) 2.5 mg capsule blister pack

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 3.025 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; purified talc; croscarmellose sodium; indigo blue; titanium dioxide; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

PAPAVERINE TEVA INJECTION Israel - English - Ministry of Health

papaverine teva injection

teva israel ltd - papaverine hydrochloride - solution for injection - papaverine hydrochloride 40 mg / 2 ml - papaverine - papaverine - antispasmodic in visceral spasm, e.g. gastrointestinal colic, biliary and urinary tract spasms. peripheral vascular disease with vasospastic element. vascular spasm associated with acute myocardial infarcion, angina pectoris, peripheral and pulmonary embolism.

ATROPINE TEVA 20 MG10 ML Israel - English - Ministry of Health

atropine teva 20 mg10 ml

teva israel ltd - atropine sulfate - solution for injection - atropine sulfate 20 mg / 10 ml - atropine - atropine - preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. treatment of sinus bradycardia, particularly if complicated by hypotension. antidote in poisoning by organophosphorus.

SPIRONOLACTONE TEVA   100 MG Israel - English - Ministry of Health

spironolactone teva 100 mg

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

CARVEDILOL TEVA  6.25 MG Israel - English - Ministry of Health

carvedilol teva 6.25 mg

teva israel ltd - carvedilol - tablets - carvedilol 6.25 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedilol teva may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

CARVEDILOL TEVA  12.5 MG Israel - English - Ministry of Health

carvedilol teva 12.5 mg

teva israel ltd - carvedilol - tablets - carvedilol 12.5 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedilol teva may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

DILTIAZEM TEVA 30 MG Israel - English - Ministry of Health

diltiazem teva 30 mg

teva israel ltd - diltiazem hydrochloride - tablets - diltiazem hydrochloride 30 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.

DILTIAZEM TEVA 60 MG Israel - English - Ministry of Health

diltiazem teva 60 mg

teva pharmaceutical industries ltd, israel - diltiazem hydrochloride - tablets - diltiazem hydrochloride 60 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.